[1] Huang LY, Chang CC, Lee YS, et al.Inhibition of Hec1 as a novel approach for treatment of primary liver cancer.Cancer Chemother Pharmacol, 2014, 74:511-520.
[2] Kitani Y, Kubota A, Furukawa M, et al.Prognostic factors for local control in patients receiving radiation therapy for early glottic cancer: anterior commissure involvement and effect of chemoradiotherapy. Eur Arch Oto rhino laryngology, 2016, 273:1011-1017.
[3] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011 年版). 临床肿瘤学杂志,2011,16: 929-946.
[4] 韩涛,马东初,丁震宇,等. 索拉非尼靶向治疗联合CIK对晚期肝细胞癌患者免疫功能和毒性反应的影响. 解放军医药杂志,2015,27:41-43,51.
[5] 周学士,任雷,彭蕾,等. 索拉非尼联合肝动脉化疗栓塞术治疗中晚期肝细胞癌疗效观察. 实用肝脏病杂志,2015,18:59-62 .
[6] Maida M, Macaluso FS, Valenza F, et al.Complete and Sustained Off-Therapy Response to Sorafenib in Advanced Hepatocellular Carcinoma. Journal of Gastrointestin Liver Dis, 2016, 25: 253-255.
[7] Tai WM, Yong WP, Lim C, et al.A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC). Ann Oncol, 2016, 27:2210-2215.
[8] Colagrande S, Regini F, Taliani GG, et al.Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up. World J Hepatol, 2015, 7:1041-1053. |
